BOCX: Positive Results from Study of RECAF Saliva Test to Detect Cancers
Submitted By Knobias ClipReport
BOCX: Positive Results from Study of RECAF Saliva Test to Detect Cancers
By Fain Hughes, fhughes@knobias.com
BioCurex Inc. (BOCX) announced results showing that its RECAF test can detect cancer with high sensitivity and specificity using a small sample of saliva. The work was done as part of an ongoing collaboration with the Goshen Center for Cancer Care in Indiana.
Saliva from cancer patients and healthy donors was tested using a slightly modified RECAF chemiluminescence assay (the chemiluminescence format was chosen for practical reasons but in light of the results found, it is anticipated that the ELISA format will perform equally well). A variety of malignancies were tested, including lung, breast and gastrointestinal cancers. The results showed that the test can detect cancer with 87% sensitivity and 91% specificity (sensitivity is the percentage of cancer patients that are positive with the test and specificity is the percentage of healthy individuals that the test reports as negative).
While the number of samples is relatively small (15 cancer patients and 22 normal donors), the statistical significance is very high (p less than 0.00025).
